---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032242"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2026-10-06T20:57:28+00:00"
generated_at: "2026-10-12T16:11:07.234799+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics closes $325,000 Second Funding, reaching $2,000,000 total loan funding

## Summary
- Nuo Therapeutics received the $325,000 Second Funding on October 6, 2026, bringing aggregate Lender funding under the Loan Agreement to $2,000,000.
- The Second Closing Date was moved from September 30 to October 6, 2026 via an Assignment, Joinder, and Amendment No. 1.
- Scott M. Pittman, a director and >10% beneficial owner, assumed $25,000 and received warrants for 4,500 shares, 458 prepayment shares, and up to 2,750 interest shares.
- Second Notes bear 12% annual interest, mature December 31, 2028, and Assuming Lenders received warrants for 18,000 shares plus 1,832 prepayment shares.
- Three new unaffiliated lenders joined, and four Assuming Lenders took the assigned $100,000 Second Funding commitment in equal $25,000 portions.

## SEC filing metadata
- accession: 0001437749-26-032242
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2026-10-06T20:57:28+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774926032242/0001437749-26-032242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774926032242/aurx20261006c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032242
- JSON: https://secwatch.observer/filing/0001437749-26-032242.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.